Real-World Study on Jintiange Capsule in the Treatment of Chronic Musculoskeletal System Pain

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2026001090

Enrollment

Unknown

Registered

2026-04-28

Start date

2026-04-30

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic musculoskeletal pain (pain lasting more than 3 months occurring in muscles, bones, joints, tendons, or soft tissues)

Interventions

Single-arm cohort study:Patients prescribed Jintiange Capsule for treatment

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age =18; 2. Patients who visited the hospital within the past year; 3. Patients prescribed Jintiange Capsule; 4. Medical records include baseline VAS scores, documented concomitant medications, duration and dosage when initiating Jintiange Capsule; 5. At least one follow-up record at week 4, 8, 12, or 24 after initial use containing VAS scores, documented concomitant medications, duration and dosage, within the enrollment period

Exclusion criteria

Exclusion criteria: 1. Patients with severe dysfunction of vital organs (heart, liver, kidney) affecting drug metabolism or study outcomes; 2. Patients with malignancies, hematological diseases, autoimmune diseases or other conditions that may interfere with study results; 3. Incomplete medical records; 4. Patients deemed unsuitable for participation by investigators

Design outcomes

Primary

Measure	Time frame
Change from baseline VAS score;	—

Countries

China

Contacts

Public ContactSu Aishan

Nanfang Hospital of Southern Medical University

nfyysas@126.com18927527665

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026